Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a person's dendritic cells mixed with tumor peptides and proteins may help the body build an effective immune response to kill tumor cells. Infusing the vaccine directly into the lymphatic system may cause a stronger immune response and kill more tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of two dendritic cell vaccines in treating patients with stage III or stage IV melanoma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Compare the safety of intralymphatic autologous type-1-polarized dendritic cell vaccine vs autologous mature dendritic cell vaccine loaded with antigenic peptides and proteins in patients with stage III or IV melanoma.
Secondary
- Determine peripheral blood CD8+ and CD4+ T-cell responses to HLA-presented melanoma epitopes and autologous tumor cells using interferon gamma and interleukin-5 ELISPOT assay.
- Compare the delayed-type hypersensitivity (DTH) responses to these regimens and DTH to autologous tumor lysates in these patients.
- Compare the DTH response to keyhole limpet hemocyanin and pan-DR epitope (PADRE) in these patients.
- Correlate treatment-associated changes in immune response with clinical outcome.
OUTLINE: This is a randomized, open-label, dose-escalation study. Patients are randomized to 1 of 2 formulations of dendritic cell (DC) vaccines.
- Arm I: Patients receive intralymphatic autologous type-1-polarized (by interleukin-1-beta, tumor necrosis factor [TNF] alfa, interferon alfa, poly-I:C, and interferon gamma) DC vaccine that has been loaded with tumor-related peptide antigens (gp100:209-217[210M] peptide, tyrosinase peptide, MART-1:27-35 peptide, MAGE-3/6, and EphA2) and proteins (keyhole limpet hemocyanin [KLH; first course] or pan-DR epitope [PADRE] [second course]) every 6 hours on days 1-4 of weeks 1 and 6.
- Arm II: Patients receive intralymphatic autologous mature (by interleukin-1-beta, TNF alfa, interleukin-6, and prostaglandin E_2) DC vaccine that has been loaded with tumor-related peptide antigens and proteins as in arm I every 6 hours on days 1-4 of weeks 1 and 6.
Patients achieving complete response receive 2 more courses of treatment (3 months apart). Patients achieving partial response receive up to 10 more courses of treatment (1 month apart) in the absence of disease progression or unacceptable toxicity.
In each arm, cohorts of 4-7 patients receive escalating doses of DC vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 7 patients experience dose-limiting toxicity.
Blood samples are obtained at baseline and periodically during and after treatment. Samples are examined by immunoenzyme techniques for immunologic measurements.
After completion of study therapy, patients are followed periodically for 10½ years and then annually thereafter.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Cancer Centers
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- UPMC Cancer Center at Magee-Womens Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Pathologically confirmed stage III or IVA (M1a) melanoma
- Recurrent and inoperable disease
- Any tumor thickness and any number of lymph nodes involved
- Asymptomatic cutaneous and nodal disease allowed
- Asymptomatic pulmonary metastatic disease (stage IVB, M1b) allowed
- No advanced symptomatic visceral disease, including any symptomatic visceral organ involvement, or disease associated with increased serum lactic dehydrogenase > 2.5 times upper limit of normal (stage IVC, M1c)
- Standard curative or palliative measures do not exist or are no longer effective
Sufficient numbers of monocytes (≥ 20 x 10^6) must be obtained for the preparation of the vaccine
- If an insufficient number of cells is obtained on first venipuncture, a second venipuncture may be performed (not exceeding 550 mL of blood within 8 weeks)
No brain metastases by contrast-enhanced CT scan or MRI
- Prior brain metastases allowed provided they were successfully treated and patient has been asymptomatic for ≥ 3 months
- HLA-A2 positive
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy ≥ 6 months
- Granulocyte count ≥ 1,500/mm³
- Lymphocyte count ≥ 500/mm³
- Platelet count > 70,000/mm³ (for venipuncture/pheresis procedure)
- Creatinine ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- Gamma-glutamyl transferase ≤ 2.5 times ULN
- Lactic dehydrogenase ≤ 2.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- Bilirubin ≤ 1.5 times ULN
- No active infection
- No sensitivity to drugs that provide local anesthesia
- No pain uncontrolled by oral analgesics, including opiates and opiate analogs
- No active autoimmune disease
- No HIV, hepatitis B, or hepatitis C positivity
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Negative pregnancy test
- No other malignancy except for nonmelanoma skin cancers or carcinoma in situ of the cervix, or other malignancy for which the patient has been continuously disease-free for ≥ 2 years
PRIOR CONCURRENT THERAPY:
- Recovered from prior surgery
- No radiotherapy, chemotherapy, or immunotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C)
- No antibiotics within the past 7 days
No systemic immunosuppressive agents, including steroids, within the past 4 weeks
- Concurrent maintenance steroids for adrenal insufficiency allowed
- No other concurrent anticancer investigational or commercial agents or therapies
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: peptide-pulsed type-1-polarized dendritic cells
intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
|
|
|
Experimental: peptide-pulsed mature non-polarized dendritic cells (cDCs)
intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Safety of intralymphatic autologous type-1-polarized dendritic cell vaccine and autologous mature dendritic cell vaccine
Zeitfenster: 7 years
|
7 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Assess immune responses to each dendritic cell vaccine outcome
Zeitfenster: 7
|
i. Peripheral blood CD8+ and CD4+ T cell responses against HLA-presented melanoma epitopes, and (in patients with available tumor tissue) against autologous tumor cells, and using IFNγ-, and IL-5- ELISPOT assays. CD8+ T cell responses (IFNγ ELISPOT) will be used as a secondary readout: the sum of the specific ELISPOT counts obtained (at week 8) with each of the individual HLA-A2-restricted peptides (less the respective counts obtained before the treatment), will be considered as a primary indication of the vaccine effectiveness. ii. Delayed type hypersensitivity (DTH) response to the mix of the melanoma-related peptides, injected intradermally in vivo, and DTH to autologous tumor lysates, in all cases when autologous tumor tissue is available. iii. Delayed type hypersensitivity (DTH) responses to KLH and PADRE injected intradermally in vivo. |
7
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Ahmad A. Tarhini, MD, MS, University of Pittsburgh
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 03-118
- PCI-UPCI-03-118
- NCI-7089
- PCI-IRB-0409071
- CDR0000504518 (Registrierungskennung: PDQ (Physician Data Query))
- NCI-2009-00125 (Registrierungskennung: CTRP (Clinical Trials Reporting System))
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Melanom (Haut)
-
Federal University of Health Science of Porto AlegreAbgeschlossenSkin-PickingBrasilien
-
Oystershell NVAbgeschlossen
-
University of Wisconsin, MilwaukeeAbgeschlossen
-
Utah State UniversityAktiv, nicht rekrutierendAbschürfungsstörung (Skin-Picking).Vereinigte Staaten
-
Jordi Gol i Gurina FoundationAbgeschlossen
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulAbgeschlossenSkin-PickingBrasilien
-
University of ChicagoAbgeschlossenTrichotillomanie | Skin-PickingVereinigte Staaten
-
University of ChicagoAbgeschlossenDermatillomanie | Pathologisches Skin Picking | Neurotische Exkoriation | Psychogene ExkoriationVereinigte Staaten
-
Karolinska InstitutetRegion StockholmAbgeschlossenTrichotillomanie | Abschürfungsstörung (Skin-Picking).Schweden
-
University of ChicagoRekrutierungTrichotillomanie (Hair-Pulling Disorder) | Skin-PickingVereinigte Staaten
Klinische Studien zur polarized dendritic cells
-
National Cancer Institute (NCI)AbgeschlossenBrustkrebs | Neoplasien der Brust | Adenokarzinome | Metastatische solide Tumore, gekennzeichnet durch HER2/Neu-ExpressionVereinigte Staaten
-
CytoCore, Inc.University Hospitals Cleveland Medical CenterBeendetSammlung zervikaler ZellenVereinigte Staaten
-
Oxford ImmunotecAbgeschlossenTuberkuloseVereinigte Staaten, Südafrika
-
University of RochesterAbgeschlossen
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterRekrutierungErbkrankheit | Pränataldiagnostik | Anomalie der KopienzahlVereinigte Staaten
-
Mayo ClinicAbgeschlossenSodbrennen | Acid Reflux-KrankheitVereinigte Staaten
-
CytoCore, Inc.University Hospitals Cleveland Medical CenterAbgeschlossenKolposkopie | BiopsieVereinigte Staaten
-
Neurotech PharmaceuticalsUniversity of California, San FranciscoAbgeschlossenRetinitis pigmentosa | Usher-Syndrom Typ 2 | Usher-Syndrom Typ 3Vereinigte Staaten
-
Duke UniversityRekrutierungCOVID-19 akutes AtemnotsyndromVereinigte Staaten
-
CliPS Co., LtdAbgeschlossenLimbus-Corneae-Insuffizienz-Syndrom | Limbus HornhautKorea, Republik von